Postdoctoral Research Associate
University of North Carolina at Chapel Hill
Danwei Shao, Pharm.D. is a T32 postdoctoral research fellow at the UNC Eshelman School of Pharmacy's Division of Pharmacotherapy and Experimental Therapeutics. His research focuses on pharmacogenomics and precision medicine in cardiovascular disease, with a particular emphasis on identifying clinical factors that enhance CYP2C19 genotype-guided antiplatelet therapy selection for patients undergoing percutaneous coronary interventions.